NICE now recommends Nucala for both severe asthma and COPD, expanding the drug’s clinical uptake across the UK’s public health service.
GSK’s Nucala will now join Sanofi’s Dupixent within the NHS’s COPD biologic maintenance add-on treatment arsenal. Credit: M7Studio / Shutterstock.com.
In another landmark for GSK’s blockbuster respiratory drug, Nucala (mepolizumab), the UK’s health watchdog has recommended the therapy’s use by the UK National Health Service (NHS) in patients with chronic obstructive pulmonary disease (COPD).
In draft guidance debuted by the UK National Institute for Health and Care Excellence (NICE), the health agency endorsed Nucala’s use in adult patients with uncontrolled COPD characterised by raised blood eosinophils. This means that patients using the NHS will have access to the IL-5 blocker as an add-on maintenance option alongside standard of care (SoC) triple inhaled therapy. Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
